[Pathogenetic principles of the therapy of retinal ischemia in vascular diseases of the fundus oculi based on studies of the role of nitrogen oxide].
Arkhipova
M M
MM
Vanin
A F
AF
D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D007511:Ischemia / Q000175:diagnosis / Q000188:drug therapy*; D019331:NG-Nitroarginine Methyl Ester / Q000627:therapeutic use; D009569:Nitric Oxide / Q000037:antagonists & inhibitors* / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000502:physiology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012171:Retinal Vessels; D019323:omega-N-Methylarginine / Q000627:therapeutic use
D000975:Antioxidants; D004791:Enzyme Inhibitors; D016194:Receptors, N-Methyl-D-Aspartate; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester